1356.9000 -37.10 (-2.66%)
NSE Dec 24, 2025 15:31 PM
Volume: 48,954
 

1356.90
-2.66%
ICICI Securities Limited
Tatva Chintan’s Q4FY23 revenue rose 26.4% YoY to Rs1.2bn as SDA revenue recovered to Rs0.5bn, up 41% YoY. However, gross profit margin dip of 400bps to 39.8% was disappointing (partly from a change in product mix) considering the company has guided for a sequential improvement in margins.
Number of FII/FPI investors increased from 19 to 31 in Sep 2025 qtr.
More from Tatva Chintan Pharma Chem Ltd.
Recommended